T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD - Villingen-Schwenningen, Germany

EuroPrevent 2019 Prof. Jacobs discusses the shift in management of diabetes based on CVOTs and explains underlying mechanisms of benefits with GLP-1RAs in diabetic patients.

Video navigation menu

Is reducing HbA1c really succesful in diabetes? 1:47
Cardiovascular outcomes trials 3:53
Underlying mechanisms of CV benefits with GLP-1RAs 6:48
New recommendations for T2DM patients 9:11

Educational information

This lecture by prof. Stephan Jacob was part of a CME accredited symposium "The preventive challenge in diabetes & CVD - A multidisciplinary approach"

Faculty

Prof. Stephan Jacob, endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.

View slides of the presentation held by Stephan Jacob

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.